GLP-2 TZ (Teduglutide)
teduglutidegattexrevestive
Approved GLP-2 analog (teduglutide) — short bowel syndrome. Gut-focused tracking framework.
- Half-life
- 2 h
- Out of system
- ~10 h
- Route
- Subcutaneous
- Level
- Intermediate
Short-acting — protocols usually dose daily. After the last dose, roughly 97% has cleared in ~10 h (five half-lives) — the window that matters for washouts, bloodwork and surgery.
What GLP-2 TZ (Teduglutide) is used for
- Approved GLP-2 analog (teduglutide) for short bowel syndrome
- Promotes intestinal-lining growth and nutrient absorption
How it's typically used
Approved: 0.05 mg/kg subcutaneous daily.
What to watch for
- Can promote polyp/intestinal growth — colonoscopy monitoring
- Risk of bowel obstruction and fluid overload
- Prescription-only; specialist-supervised
About Other research compounds
- What they are
- Nootropics, metabolic agents, and research compounds that don't fit the other classes.
- How they're run
- Route and schedule vary widely — check the individual entry.
- What to watch
- This is the least-characterised corner of the atlas. Read the full guide, and treat anything without published human data as exactly that.
Full guide
GLP-2 TZ (Teduglutide): A Tracking Guide for the Gut-Curious
A pragmatic look at teduglutide, the approved GLP-2 analog, and how a self-experimenter might track gut-related outcomes.
Other other research compounds
Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.